Alligator Bioscience AB (FRA:7AL)
€ 0.0215 -0.023 (-51.69%) Market Cap: 17.75 Mil Enterprise Value: 14.46 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Alligator Bioscience AB at Redeye Growth Day (Virtual) Transcript

Jun 02, 2022 / NTS GMT
Release Date Price: €0.084176 (-6.29%)
SÃ;ren Bregenholt
Alligator Bioscience AB - CEO

¸ -

Hi. I'm Søren Bregenholt. I'm the CEO of Alligator Bioscience. It's a pleasure being with you today. So Alligator Bioscience is a clinical-stage biotech company with a deep and broad pipeline in best-in-class, both monoclonal and bispecific, antibodies and a range of novel monoclonal bispecific antibody technologies. We are listed on NASDAQ in Stockholm and headquartered in Lund in the southern part of Sweden.

Our lead asset, mitazalimab, is being developed in first-line pancreatic cancer in combination with chemotherapy. And we are currently conducting a Phase II study here. In addition, we have a differentiated pipeline with several near- to mid-term value drivers. And our leading antibody technologies are well positioned to sustain longer-term value generation for Alligator. In addition, we have several pipeline assets that are mature for out-licensing.

We built a strong team with a proven track record for global biotech and pharma, making us well suited to deliver both in product development, on operational execution of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot